West Island Brands - CEO, Boris Ziger
CEO, Boris Ziger
Source: Small Cap Power
  • A Matica (CSE:MMJ) subsidiary has signed a purchase agreement with a Franchise Cannabis subsidiary to acquire cannabis genetic material
  • Through the agreement, Matica’s RoyalMax Biotechnology will obtain THC varieties from Franchise’s Rangers Pharmaceuticals
  • Franchise Cannabis has a collection of over 220 cannabis strains, kept within the first legally registered seedbank in Europe
  • The varieties include Wakeford, Pineapple Express, and Triumphant.
  • Matica (MMJ) is up 25.00 per cent, and is currently trading for 2.5 cents per share

A Matica (CSE:MMJ) subsidiary has signed a purchase agreement with a Franchise Cannabis subsidiary to acquire cannabis genetic material.

The company’s RoyalMax Biotechnology Canada entered the agreement with Franchise’s Rangers Pharmaceuticals. 

Through the purchase agreement, RoyalMax will obtain high-THC varieties from Franchise’s seedbank, the first legally registered one in Europe. The varieties include Wakeford, Pineapple Express, and Triumphant, which Matica expects will receive a warm welcome in Canada.

Franchise Cannabis has over 220 diverse cannabis strains, bred by world-renowned breeder Charles Scott.

He has previously won several awards for his THC strains, such as Love Potion #1, Willie Nelson, and Pink Kush. He has also won 19 Cannabis Cups, and been inducted into the High Times Hall of Fame.  

Matica believes that it will gain a new competitive advantage by injecting new, exciting cannabis strains into Canada’s market.

Matica’s CEO, Boris Ziger, welcomed the opportunities which the purchase agreement brings.

“RoyalMax will introduce new cannabis varieties unique to the Canadian market. Currently there is a lack of genetic diversity within the Canadian market. 

“RoyalMax will have the ability to offer new and unique product varieties to our consumers. Through this relationship, RoyalMax will benefit from one of the most complete and sought-after genetics collections in the world,” he said.

Franchise Cannabis’ CEO, Clifford Starke, also commented on the agreement.

“Matica will have a distinct advantage within the Canadian market by utilizing some of our top strains, such as the highly unique and potent Triumphant, which have not yet been introduced to the Canadian market.

“Franchise is excited to fill this gap and work with innovators in the industry, such as Matica, to effectively cultivate and distribute product based on our unique cultivars,” he said.

Matica (MMJ) is up 25.00 per cent, and is trading for 2.5 cents per share, at 11:59am EDT.

More From The Market Online

The Market Online’s Weekly Cannabis Report – April 19, 2024

Cannabis news this week: Canopy Growth shareholders overwhelmingly voted to approve a new class of exchangeable shares.

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.